How to Get Leqvio (Inclisiran) in Arkansas

What Leqvio Is and Why It Matters for Arkansas Patients

Leqvio (inclisiran) is an RNA interference (RNAi) therapy that silences PCSK9 synthesis in hepatocytes, reducing LDL-C by roughly 50% with only two injections per year after the loading phase. The FDA granted approval on December 22, 2021, for adults with HeFH or established ASCVD who are already on maximally tolerated statin therapy. Cardiovascular disease remains the leading cause of death in Arkansas, with the state's age-adjusted heart disease mortality rate exceeding the national average according to CDC data. That burden creates a real clinical need for durable, high-efficacy LDL-C lowering options beyond statins alone.

Inclisiran works differently from monoclonal antibody PCSK9 inhibitors such as evolocumab (Repatha) or alirocumab (Praluent). Rather than blocking circulating PCSK9 protein, it prevents PCSK9 from being made in the first place. A conjugated GalNAc ligand delivers a small interfering RNA directly to liver cells, where it degrades PCSK9 mRNA. Because the silencing effect persists, a dose every six months sustains the reduction without daily pills or monthly injections. Inclisiran's mechanism and pharmacokinetics are detailed in the FDA prescribing information.

Arkansas has approximately 58,000 adults living with diagnosed familial hypercholesterolemia, and a larger population with ASCVD whose LDL-C remains above guideline targets despite statin therapy. Getting access to inclisiran requires navigating prescriber availability, insurance requirements, and specialty pharmacy logistics. Each step is described below.

Arkansas Eligibility: Who Qualifies for a Leqvio Prescription

Patients in Arkansas who meet FDA-approved indications are eligible candidates. Two populations qualify. First, adults with heterozygous familial hypercholesterolemia (HeFH) confirmed by genetic testing or clinical criteria such as the Simon Broome or Dutch Lipid Clinic Network score. Second, adults with established ASCVD, defined as prior myocardial infarction, stroke, peripheral arterial disease, or coronary revascularization, whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy, often combined with ezetimibe.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states that for very high-risk ASCVD patients with LDL-C persistently at or above 70 mg/dL on maximally tolerated lipid-lowering therapy, a PCSK9 inhibitor is a Class I, Level A recommendation. Inclisiran falls within that class even though guideline text was written before its broad adoption.

Clinical trial data support this threshold. In ORION-10 (N=1,561, statin-treated ASCVD patients, NEJM 2020), inclisiran 284 mg produced a 52.3% placebo-adjusted reduction in LDL-C at Day 510 (P<0.001) [1]. In ORION-11 (N=1,617, HeFH or ASCVD, NEJM 2020), the placebo-adjusted LDL-C reduction was 49.9% at Day 510 (P<0.001) [1]. Both trials used the twice-yearly maintenance schedule after loading doses at Day 1 and Day 90.

Patients on bile acid sequestrants, fibrates, or niacin may still qualify. Contraindications are limited: active hepatic disease and pregnancy require deferral. Renal impairment does not require dose adjustment based on current FDA labeling.

Labs Required Before a Leqvio Prescription in Arkansas

A prescriber needs a current lipid panel before writing the order. Most Arkansas providers and telehealth platforms require labs drawn within the past 90 days, though some accept 180-day results if the patient's statin regimen has not changed.

The minimum lab set includes:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
• ALT and AST (hepatic function baseline, per FDA prescribing information)
• Basic metabolic panel to document renal function

For HeFH diagnosis confirmation, a lipid genetics panel or a prior genetic test result helps document indication. The FH Foundation clinical guidelines recommend using the Dutch Lipid Clinic Network (DLCN) score to establish probable or definite HeFH when genetic results are pending or unavailable.

Labs can be ordered through any Arkansas-licensed laboratory. Quest Diagnostics has 14 patient service centers in Arkansas. LabCorp operates additional draw sites. Telehealth providers using the HealthRX platform can e-order labs to either network, with results returned digitally for the prescribing physician to review before finalizing the inclisiran prescription.

After the first injection, a follow-up lipid panel at approximately 90 days confirms LDL-C response. The ORION-9 trial (N=482, HeFH patients) showed that the LDL-C nadir occurs around Day 90 and is then sustained through Day 180, the time point of the next maintenance dose.

How to Find a Prescriber in Arkansas (In-Person and Telehealth)

Inclisiran must be administered by a licensed healthcare professional, not self-injected by the patient. The prescription, however, can be written by any Arkansas-licensed prescriber with appropriate scope: MD, DO, NP with prescriptive authority, or PA with a collaborative practice agreement and prescriptive authority.

In-person specialists. The University of Arkansas for Medical Sciences (UAMS) Cardiovascular Institute in Little Rock maintains a lipid clinic that prescribes PCSK9 inhibitors including inclisiran. Arkansas Heart Hospital also has outpatient cardiology services. Referral from a primary care provider typically shortens wait times at specialty lipid clinics.

Telehealth prescribers. Arkansas enacted telehealth parity laws that allow licensed providers to conduct a valid patient-provider relationship via synchronous audiovisual encounter and then prescribe. Inclisiran does not fall under the federal Ryan Haight Act restrictions that apply to controlled substances, so a standard telehealth visit is sufficient to initiate the prescription. The Arkansas State Medical Board confirms that telemedicine prescribing follows the same standard of care as in-person prescribing. Telehealth platforms such as HealthRX connect Arkansas patients to board-certified cardiologists and internal medicine physicians who can review labs, confirm indication, and generate the Leqvio prescription within 24 to 48 hours of the visit.

NP and PA prescribers. Arkansas Nurse Practice Act, updated in 2019, grants full practice authority to APRNs who have completed the required collaborative period. A certified nurse practitioner or physician assistant licensed in Arkansas may therefore prescribe inclisiran independently or under collaborative agreement, respectively. No restriction limits PCSK9 inhibitor prescribing to cardiologists only, though payer prior authorization forms often ask for specialist documentation.

The HealthRX Access Framework for inclisiran in Arkansas follows four steps: (1) telehealth visit with lab review, (2) prescription generation and specialty pharmacy routing, (3) prior authorization submission with documentation package, and (4) in-office or clinic administration appointment coordinated with the specialty pharmacy delivery.

Prior Authorization in Arkansas: What You Will Need

Prior authorization (PA) is required by Arkansas Medicaid and by most commercial plans including Arkansas Blue Cross Blue Shield, QualChoice, and Ambetter. The PA process is the most common bottleneck and takes 5 to 14 business days if submitted with complete documentation on the first attempt.

Standard documentation required for an Arkansas Leqvio PA includes:

• Current lipid panel showing LDL-C above plan threshold (often 70 mg/dL for ASCVD, 100 mg/dL for HeFH without ASCVD)
• Evidence of maximally tolerated statin therapy (drug name, dose, duration, typically 12 weeks minimum)
• Documentation of statin intolerance if applicable, including at least two documented statin trials per ACC statin intolerance guidance
• HeFH diagnosis (genetic report or DLCN score of 6 or higher) OR ASCVD event documentation (catheterization report, hospital discharge summary, ABI study)
• Prescriber letter of medical necessity

Arkansas Medicaid (Arkansas DHS) covers inclisiran under the pharmacy benefit with PA for both HeFH and ASCVD indications, but approval is classified as "limited PA," meaning it requires annual renewal and the first approval may require specialist attestation. CMS guidance on PCSK9 inhibitor coverage policy outlines the criteria that most state Medicaid programs model.

Commercial plan appeal rates for PCSK9 inhibitors have improved since 2020. A 2021 analysis published in the Journal of the American College of Cardiology found that 58% of initial PCSK9 inhibitor PA requests were approved on first submission when complete clinical documentation accompanied the request, rising to 81% after first appeal. Submitting with a full documentation package from the start is the most reliable way to avoid delay.

Novartis offers the Leqvio Co-Pay Assistance Program for commercially insured patients. Eligible patients may pay as little as $0 per dose. Patients without insurance or with Medicaid may qualify for the Novartis Patient Assistance Program (PAP). Both programs are accessible through the Novartis US website and through the HealthRX care coordination team.

How Inclisiran Is Dispensed and Administered in Arkansas

Leqvio is a specialty drug distributed through specialty pharmacies. It is not stocked on standard retail pharmacy shelves at Walgreens or CVS, though specialty arms of those chains may be able to order it. Primary specialty pharmacy channels include Accredo (Express Scripts), CVS Specialty, Biologics by McKesson, and Diplomat Pharmacy.

Because inclisiran requires in-office or clinic administration, the logistics chain runs differently from most medications. The specialty pharmacy ships the prefilled syringe directly to the prescriber's office or clinic, not to the patient's home. The prescriber or a licensed clinical staff member administers the injection subcutaneously in the upper arm, abdomen, or thigh. Administration takes under two minutes.

The timeline from prescription to first injection in Arkansas typically runs 10 to 21 days when prior authorization is in place, or 3 to 7 days for patients using manufacturer assistance programs that bypass insurance adjudication.

503A compounding pharmacies. Arkansas is home to several 503A-licensed compounding pharmacies that are legally permitted to compound medications for individual patient prescriptions. Inclisiran, as an FDA-approved product, cannot be compounded as a direct copy under federal law. However, 503A pharmacies can prepare office-use preparations under specific shortage or patient-specific exemptions. FDA 503A regulations define the boundaries. At present, branded Leqvio through the standard specialty pharmacy route is the most legally straightforward path for Arkansas patients.

Refrigeration requirements: Leqvio must be stored at 36 to 77 degrees Fahrenheit (2 to 25 degrees Celsius). If shipping to a provider's office, cold-chain packaging from the specialty pharmacy maintains this range. FDA storage requirements are specified in the full prescribing information.

Transferring an Existing Leqvio Prescription to Arkansas

Patients who received Leqvio in another state and have relocated to Arkansas can transfer the prescription and continue therapy without restarting the loading dose sequence, provided the following conditions are met.

First, the prescribing provider must be licensed in Arkansas or a new Arkansas-licensed provider must assume prescribing responsibility. A prescription written by an out-of-state provider cannot be filled by an Arkansas specialty pharmacy unless the prescriber holds Arkansas licensure or the prescription is transferred to an Arkansas-licensed provider.

Second, the specialty pharmacy may need to update the ship-to address to an Arkansas clinical site for administration. Because inclisiran is administered in a clinical setting, the patient cannot simply redirect a home shipment.

Third, the new Arkansas provider should document continuity of therapy, including the date of the last injection, to maintain the six-month dosing interval. A delay of more than four weeks past the scheduled maintenance dose does not require restarting the loading sequence per current FDA labeling, but it may affect the timing of peak LDL-C reduction. The treating provider should obtain a current lipid panel to assess LDL-C before resuming.

The ACC/AHA 2018 Cholesterol Guideline recommends measuring LDL-C 4 to 12 weeks after initiating or changing lipid-lowering therapy to confirm response and adherence, a standard that applies equally to therapy transfers.

Safety Profile and Monitoring While on Leqvio

Inclisiran has a favorable safety profile based on the combined ORION program data. In pooled analysis of ORION-9, ORION-10, and ORION-11, the most common adverse events were injection-site reactions (8.2% inclisiran vs. 1.8% placebo), limb pain (2.1% vs. 1.1%), and urinary tract infections (5.0% vs. 3.6%) [1]. Serious adverse event rates were similar between inclisiran and placebo arms.

Hepatotoxicity signals were not observed in the ORION program. ALT and AST elevations greater than three times the upper limit of normal occurred in <1% of inclisiran-treated patients, comparable to placebo. The FDA prescribing information does not require routine liver function monitoring beyond baseline, though clinicians may monitor at their discretion.

Drug interactions are minimal. Inclisiran is not metabolized by cytochrome P450 enzymes and has no known clinically significant drug-drug interactions per published pharmacokinetic data. Patients on anticoagulants, immunosuppressants, or complex polypharmacy regimens do not require dose adjustment.

Pregnancy: inclisiran is not recommended in pregnancy. LDL-C is not a target for reduction during pregnancy, and no safety data exist for fetal exposure. Patients who become pregnant while on inclisiran should notify their prescriber immediately. The FDA Pregnancy and Lactation Labeling Rule data for inclisiran is based on animal studies showing no reproductive toxicity at clinical doses, but human data remain absent.

Ongoing monitoring after each injection should include a lipid panel at 90 days to confirm the expected LDL-C nadir. If LDL-C reduction is less than 30% from baseline, adherence to concomitant statin therapy and potential secondary causes of hypercholesterolemia should be investigated. The European Atherosclerosis Society recommends an LDL-C target of <55 mg/dL for very high-risk patients, a threshold achievable with statin plus inclisiran combination in most patients who responded in the ORION trials.

Cost, Insurance, and Patient Assistance in Arkansas

The list price for Leqvio is approximately $3,250 per injection (roughly $6,500 per year for the two maintenance doses after the loading phase). For commercially insured Arkansas patients, the Novartis co-pay card can reduce out-of-pocket cost substantially. Patients who exhaust their deductible early in the plan year sometimes find that specialty tier cost-sharing applies only to the first one or two doses before the out-of-pocket maximum is met.

Arkansas Medicaid covers inclisiran under the pharmacy benefit with prior authorization. The state's preferred drug list (PDL) places PCSK9 inhibitors in a non-preferred specialty tier, which requires PA demonstrating failure of or contraindication to statins plus documented ASCVD or HeFH.

For uninsured Arkansans, the Novartis Patient Assistance Program provides inclisiran at no cost to eligible patients with household income at or below 400% of the federal poverty level. Applications are submitted through the NovartisPatientAssistance.com portal, and a HealthRX care coordinator can help with form completion. Approval typically takes 10 to 14 business days.

Medicare Part D covers inclisiran as a specialty drug. The Inflation Reduction Act's $2,000 annual out-of-pocket cap beginning in 2025 substantially reduces the cost burden for Medicare beneficiaries who previously faced uncapped specialty tier cost-sharing. CMS has published guidance on the 2025 Medicare Part D redesign that applies to inclisiran and similar specialty drugs.